SOPHiA GENETICS (NASDAQ:SOPH) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research note released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $12.00 target price on the stock.

SOPH has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reissued a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS has an average rating of “Moderate Buy” and an average target price of $9.00.

SOPHiA GENETICS Trading Up 7.8%

Shares of SOPHiA GENETICS stock opened at $6.33 on Monday. The firm has a market capitalization of $531.02 million, a PE ratio of -12.17 and a beta of 0.96. SOPHiA GENETICS has a twelve month low of $2.92 and a twelve month high of $6.50. The firm’s 50-day moving average price is $5.26 and its 200 day moving average price is $5.03. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Insider Buying and Selling

In other news, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the transaction, the insider directly owned 614,887 shares in the company, valued at $3,178,965.79. The trade was a 1.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.10, for a total value of $26,953.50. Following the completion of the sale, the chief technology officer owned 192,171 shares of the company’s stock, valued at $980,072.10. This trade represents a 2.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock worth $959,913 in the last 90 days. Corporate insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the stock. 1492 Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter worth $973,000. Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS during the 4th quarter valued at about $2,009,000. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $2,157,000. Royal Bank of Canada grew its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the period. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the first quarter worth about $1,772,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.